Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 1/2017

01-07-2017 | Review

Current strategies in the diagnosis of endometrial cancer

Authors: Tamar Tzur, Roi Kessous, Adi Y. Weintraub

Published in: Archives of Gynecology and Obstetrics | Issue 1/2017

Login to get access

Abstract

Purpose

Endometrial cancer is the most common gynecological malignancy in developed countries. There are no uniform recommendations for endometrial cancer screening in the general population. Therefore, it is of paramount importance that the primary physician profoundly understands, and is familiar with the methods for prevention and early detection of endometrial cancer. The aim of this review is to provide the primary physician with a toolbox to reach these goals.

Methods

We performed a systemic review to summarize the current strategies to diagnose and prevent endometrial cancer. Many published articles from the last years were identified and included.

Results

A systematic review that summarizes the important subjects in the diagnosis and prevention of endometrial cancer.

Conclusion

Maintaining a high index of suspicion and obtaining endometrial biopsies from all suspected patients is the key for achieving a timely diagnosis.
Literature
1.
Committee A, ACOG Committee Opinion (2003) Routine cancer screening. Number 247, December 2000. Int J Gynaecol Obstet 82(2):241–245CrossRef
2.
Smith RA, Cokkinides V (2005) Eyre HJ (2005) American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 55(1):31–44 (quiz 55–56) PubMedCrossRef
3.
4.
Weiss NS, Szekely DR, Austin DF (1976) Increasing incidence of endometrial cancer in the United States. N Engl J Med 294(23):1259–1262PubMedCrossRef
5.
Ziel HK, Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293(23):1167–1170PubMedCrossRef
6.
Smith DC et al (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293(23):1164–1167PubMedCrossRef
7.
8.
Austin DF, Roe KM (1982) The decreasing incidence of endometrial cancer: public health implications. Am J Publ Health 72(1):65–68CrossRef
9.
10.
Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591PubMedCrossRef
11.
Lindemann K et al (2010) Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027. Int J Cancer 127(11):2661–2668PubMedCrossRef
12.
Gao Y et al (2016) The prevalence of endometrial cancer in pre- and postmenopausal Chinese women. Menopause
13.
Jamison PM et al (2013) Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992–2008. Cancer Epidemiol Biomark Prev 22(2):233–241CrossRef
14.
15.
Hill HA et al (1996) Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet Gynecol 88(6):919–926PubMedCrossRef
16.
Sonoda Y, Barakat RR (2006) Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol 20(2):363–377PubMedCrossRef
17.
Brinton LA et al (2013) Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 129(2):277–284PubMedPubMedCentralCrossRef
18.
19.
20.
21.
Matias-Guiu X, Prat J (2013) Molecular pathology of endometrial carcinoma. Histopathology 62(1):111–123PubMedCrossRef
22.
Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13(3):295–308PubMedCrossRef
23.
24.
Armstrong AJ et al (2012) Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol 19(5):562–571PubMedCrossRef
25.
Gol K et al (2001) Endometrial patterns and endocrinologic characteristics of asymptomatic menopausal women. Gynecol Endocrinol 15(1):63–67PubMedCrossRef
26.
Ash SJ, Farrell SA, Flowerdew G (1996) Endometrial biopsy in DUB. J Reprod Med 41(12):892–896PubMed
27.
Park JC et al (2011) Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clin Exp Reprod Med 38(1):42–46PubMedPubMedCentralCrossRef
28.
Baak JP et al (2005) The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 103(11):2304–2312PubMedPubMedCentralCrossRef
29.
Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 56(2):403–412PubMedCrossRef
30.
Zaino RJ et al (2006) Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106(4):804–811PubMedCrossRef
31.
Salman MC et al (2010) Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia. J Gynecol Oncol 21(2):97–101PubMedPubMedCentralCrossRef
32.
33.
The Writing Group for the PEPI Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 275(5):370–375CrossRef
34.
Herrinton LJ, Weiss NS (1993) Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 3(3):308–318PubMedCrossRef
35.
Archer DF (2001) The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 8(4):245–251PubMedCrossRef
36.
Pike MC et al (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89(15):1110–1116PubMedCrossRef
37.
Anderson GL et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13):1739–1748PubMedCrossRef
38.
Mourits MJ et al (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97(5 Pt 2):855–866PubMed
39.
Killackey MA, Hakes TB, Pierce VK (1985) Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69(2):237–238PubMed
40.
Iqbal J et al (2012) Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev 38(4):318–328PubMedCrossRef
41.
Early Breast Cancer Trialists’ Collaborative G et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784CrossRef
42.
Committee on Practice B.-G. (2012) ACOG practice bulletin no. 126: Management of gynecologic issues in women with breast cancer. Obstet Gynecol 119(3):666–682CrossRef
43.
Zeleniuch-Jacquotte A et al (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84(7):975–981PubMedPubMedCentralCrossRef
44.
Lukanova A et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108(3):425–432PubMedCrossRef
45.
Hardiman P, Pillay OC, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361(9371):1810–1812PubMedCrossRef
46.
Gadducci A et al (2005) Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 20(4):200–208PubMedCrossRef
47.
Giudice LC (2006) Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 20(2):235–244PubMedCrossRef
48.
Brinton LA et al (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167(5):1317–1325PubMedCrossRef
49.
Xu WH et al (2004) Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. Int J Cancer 108(4):613–619PubMedCrossRef
50.
Zhang Y et al (2010) The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol 117(1):41–46PubMedCrossRef
51.
Noto H et al (2010) Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 24(5):345–353PubMedCrossRef
52.
Soliman PT et al (2006) Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106(11):2376–2381PubMedCrossRef
53.
Friberg E et al (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50(7):1365–1374PubMedCrossRef
54.
Vrachnis N et al (2016) Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives. Arch Gynecol Obstet 293(2):239–246PubMedCrossRef
55.
Potischman N et al (1996) Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 88(11):756–758PubMedCrossRef
56.
Renehan AG et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578PubMedCrossRef
57.
Pellerin GP, Finan MA (2005) Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol 193(5):1640–1644PubMedCrossRef
58.
Bharati R et al (2014) Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer? Gynecol Oncol 133(2):287–292PubMedPubMedCentralCrossRef
59.
Kitson SJ, Evans DG, Crosbie EJ (2017) Identifying high-risk women for endometrial cancer prevention strategies: proposal of an endometrial cancer risk prediction model. Cancer Prev Res (Phila) 10(1):1–13CrossRef
60.
Hampel H (2014) NCCN increases the emphasis on genetic/familial high-risk assessment in colorectal cancer. J Natl Compr Canc Netw 12(5 Suppl):829–831PubMedCrossRef
61.
Bonadona V et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305(22):2304–2310PubMedCrossRef
62.
Elmasry K et al (2009) Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study. Fam Cancer 8(4):431–439PubMedCrossRef
63.
64.
Sehgal R et al (2014) Lynch syndrome: an updated review. Genes (Basel) 5(3):497–507
65.
Vasen HF et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMedCrossRef
66.
Umar A et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedPubMedCentralCrossRef
67.
Tzortzatos G et al (2015) The gynecological surveillance of women with Lynch syndrome in Sweden. Gynecol Oncol
68.
69.
70.
Painter JN et al (2015) Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 24(5):1478–1492PubMedCrossRef
71.
Thompson DJ et al (2016) CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer 23(2):77–91PubMedPubMedCentralCrossRef
72.
Fraser IS et al (2007) A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 87(3):466–476PubMedCrossRef
73.
American College of O. and Gynecologists (2005) ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 106(2):413–425CrossRef
74.
Seebacher V et al (2009) The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer 9:460PubMedPubMedCentralCrossRef
75.
Committee on Practice B.-G. (2013) Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol 122(1):176–185CrossRef
76.
Haidopoulos D et al (2010) Risk factors in women 40 years of age and younger with endometrial carcinoma. Acta Obstet Gynecol Scand 89(10):1326–1330PubMedCrossRef
77.
Smith-Bindman R, Weiss E, Feldstein V (2004) How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 24(5):558–565PubMedCrossRef
78.
Osmers R et al (1989) Vaginosonographic measurement of the postmenopausal endometrium in the early detection of endometrial cancer. Geburtshilfe Frauenheilkd 49(3):262–265PubMedCrossRef
79.
Seckin B et al (2016) Diagnostic value of sonography for detecting endometrial pathologies in postmenopausal women with and without bleeding. J Clin Ultrasound
80.
Timmermans A et al (2010) Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 116(1):160–167PubMedCrossRef
81.
Bouzid A, Ayachi A, Mourali M (2015) Value of ultrasonography to predict the endometrial cancer in postmenopausal bleeding. Gynecol Obstet Fertil 43(10):652–658PubMedCrossRef
82.
Sladkevicius P, Valentin L (2016) Prospective validation of two mathematical models to calculate the risk of endometrial malignancy in patients with postmenopausal bleeding and sonographic endometrial thickness ≥4.5 mm. Eur J Cancer 59:179–188PubMedCrossRef
83.
Anastasiadis PG et al (2000) Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 21(2):180–183PubMed
84.
Dreisler E et al (2009) Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Ultrasound Obstet Gynecol 33(1):102–108PubMedCrossRef
85.
Dreisler E et al (2009) Value of endometrial thickness measurement for diagnosing focal intrauterine pathology in women without abnormal uterine bleeding. Ultrasound Obstet Gynecol 33(3):344–348PubMedCrossRef
86.
Lieng M et al (2008) Flow differences between endometrial polyps and cancer: a prospective study using intravenous contrast-enhanced transvaginal color flow Doppler and three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynecol 32(7):935–940PubMedCrossRef
87.
Perez-Medina T et al (2002) Predicting atypia inside endometrial polyps. J Ultrasound Med 21(2):125–128PubMedCrossRef
88.
Lieng M, Istre O, Qvigstad E (2010) Treatment of endometrial polyps: a systematic review. Acta Obstet Gynecol Scand 89(8):992–1002PubMedCrossRef
89.
Fischerova D, Cibula D (2015) Ultrasound in gynecological cancer: is it time for re-evaluation of its uses? Curr Oncol Rep 17(6):28PubMedCrossRef
90.
Fischerova D (2011) Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: a review. Ultrasound Obstet Gynecol 38(3):246–266PubMedCrossRef
91.
Wang Y et al (2014) Time-intensity curve parameters in rectal cancer measured using endorectal ultrasonography with sterile coupling gels filling the rectum: correlations with tumor angiogenesis and clinicopathological features. Biomed Res Int 2014:587806PubMedPubMedCentral
92.
Liu Y et al (2016) Quantitative contrast-enhanced ultrasonography for the differential diagnosis of endometrial hyperplasia and endometrial neoplasms. Oncol Lett 12(5):3763–3770PubMedPubMedCentral
93.
Kierans AS et al (2014) Utility of conventional and diffusion-weighted MRI features in distinguishing benign from malignant endometrial lesions. Eur J Radiol 83(4):726–732PubMedCrossRef
94.
Shen SH et al (2008) Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer. AJR Am J Roentgenol 190(2):481–488PubMedCrossRef
95.
Takeuchi M et al (2005) Pathologies of the uterine endometrial cavity: usual and unusual manifestations and pitfalls on magnetic resonance imaging. Eur Radiol 15(11):2244–2255PubMedCrossRef
96.
Fujii S et al (2008) Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results. Eur Radiol 18(2):384–389PubMedCrossRef
97.
Wang J et al (2010) The value of the apparent diffusion coefficient in differentiating stage IA endometrial carcinoma from normal endometrium and benign diseases of the endometrium: initial study at 3-T magnetic resonance scanner. J Comput Assist Tomogr 34(3):332–337PubMedCrossRef
98.
Takeuchi M, Matsuzaki K, Nishitani H (2009) Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion. Acta Radiol 50(8):947–953PubMedCrossRef
99.
Bakir B et al (2017) Role of diffusion weighted MRI in the differential diagnosis of endometrial cancer, polyp, hyperplasia, and physiological thickening. Clin Imaging 41:86–94PubMedCrossRef
100.
Lai CR, Hsu CY, Li AF (2012) Degenerative necrotic endometrial debris in Papanicolaou smears. The role in the prediction of endometrial pathology. Am J Clin Pathol 137(2):290–294PubMedCrossRef
101.
Zhou J, Tomashefski J Jr, Khiyami A (2007) Diagnostic value of the thin-layer, liquid-based Pap test in endometrial cancer: a retrospective study with emphasis on cytomorphologic features. Acta Cytol 51(5):735–741PubMedCrossRef
102.
Kir G et al (2014) Significance of foamy histiocytes in cervical smears from postmenopausal women. Acta Cytol 58(1):42–46PubMedCrossRef
103.
Schnatz PF et al (2006) Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 107(3):701–708PubMedCrossRef
104.
105.
Sams SB, Currens HS, Raab SS (2012) Liquid-based Papanicolaou tests in endometrial carcinoma diagnosis. Performance, error root cause analysis, and quality improvement. Am J Clin Pathol 137(2):248–254PubMedCrossRef
106.
Serdy K et al (2016) The Value of papanicolaou tests in the diagnosis of endometrial carcinoma: a large study cohort from an Academic Medical Center. Am J Clin Pathol 145(3):350–354PubMedCrossRef
107.
Levine L, Lucci JA 3rd, Dinh TV (2003) Atypical glandular cells: new Bethesda Terminology and Management Guidelines. Obstet Gynecol Surv 58(6):399–406PubMed
108.
Wright TC Jr et al (2007) 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11(4):201–222PubMedCrossRef
109.
Sanam M, Majid MM (2015) Comparison the diagnostic value of dilatation and curettage versus endometrial biopsy by Pipelle: a clinical trial. Asian Pac J Cancer Prev 16(12):4971–4975PubMedCrossRef
110.
Fakhar S et al (2008) Validity of pipelle endometrial sampling in patients with abnormal uterine bleeding. Ann Saudi Med 28(3):188–191PubMedCrossRef
111.
Abdelazim IA, Aboelezz A, Abdulkareem AF (2013) Pipelle endometrial sampling versus conventional dilatation and curettage in patients with abnormal uterine bleeding. J Turk Ger Gynecol Assoc 14(1):1–5PubMedPubMedCentralCrossRef
112.
Abdelazim IA et al (2015) Accuracy of endometrial sampling compared to conventional dilatation and curettage in women with abnormal uterine bleeding. Arch Gynecol Obstet 291(5):1121–1126PubMedCrossRef
113.
Guido RS et al (1995) Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J Reprod Med 40(8):553–555PubMed
114.
115.
Epstein E et al (2001) Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 80(12):1131–1136PubMedCrossRef
116.
Gebauer G et al (2001) Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol 184(2):59–63PubMedCrossRef
Metadata
Title
Current strategies in the diagnosis of endometrial cancer
Authors
Tamar Tzur
Roi Kessous
Adi Y. Weintraub
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 1/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-017-4391-z

Other articles of this Issue 1/2017

Archives of Gynecology and Obstetrics 1/2017 Go to the issue

Maternal-Fetal Medicine

Higher prevalence of vitamin D deficiency in German pregnant women compared to non-pregnant women

Gynecologic Oncology

Liquid-based endometrial cytology associated with curettage in the investigation of endometrial carcinoma in a population of 1987 women

News and Views

Presentation and management of vesicovaginal fistulae after delivery at a German women’s hospital

General Gynecology

Vaginal hysterectomy versus laparoscopically assisted vaginal hysterectomy for large uteri between 280 and 700 g: a randomized controlled trial

General Gynecology

Diagnosis and management of heterotopic pregnancy following embryo transfer: clinical analysis of 55 cases from a single institution

Guidelines and Position Statements

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS)